{"title":"奈韦拉平诱发史蒂文斯约翰逊综合征","authors":"H. Prajapati, Neetu Bala, D. Kansal","doi":"10.53411/jpadr.2020.1.2.6","DOIUrl":null,"url":null,"abstract":"Introduction: Severe and life-threatening SJS is more common with nevirapine than with other NNRTIs \nCase presentation: A 56-year-old male patient presented with a complaint of lesions all over the body with a burning sensation for 4 days. He was on an ART regimen, containing zidovudine, lamivudine, and efavirenz combination for 4 years. But patient accidentally started nevirapine and after 10 days he developed maculopapular lesions which were diagnosed as SJS syndrome. There was a history of rash with nevirapine when ART was started initially in 2012. This incident of an adverse event could be assigned a term \"probable\" according to the WHO-UMC scale for causality assessment as the re-challenge was found positive. \nConclusion: Physicians and patients must be aware of this adverse effect on early diagnosis and treatment.","PeriodicalId":388338,"journal":{"name":"Journal of Pharmacovigilance and Drug Research","volume":"148 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nevirapine induced Stevens Johnson syndrome\",\"authors\":\"H. Prajapati, Neetu Bala, D. Kansal\",\"doi\":\"10.53411/jpadr.2020.1.2.6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Severe and life-threatening SJS is more common with nevirapine than with other NNRTIs \\nCase presentation: A 56-year-old male patient presented with a complaint of lesions all over the body with a burning sensation for 4 days. He was on an ART regimen, containing zidovudine, lamivudine, and efavirenz combination for 4 years. But patient accidentally started nevirapine and after 10 days he developed maculopapular lesions which were diagnosed as SJS syndrome. There was a history of rash with nevirapine when ART was started initially in 2012. This incident of an adverse event could be assigned a term \\\"probable\\\" according to the WHO-UMC scale for causality assessment as the re-challenge was found positive. \\nConclusion: Physicians and patients must be aware of this adverse effect on early diagnosis and treatment.\",\"PeriodicalId\":388338,\"journal\":{\"name\":\"Journal of Pharmacovigilance and Drug Research\",\"volume\":\"148 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacovigilance and Drug Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53411/jpadr.2020.1.2.6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacovigilance and Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53411/jpadr.2020.1.2.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Introduction: Severe and life-threatening SJS is more common with nevirapine than with other NNRTIs
Case presentation: A 56-year-old male patient presented with a complaint of lesions all over the body with a burning sensation for 4 days. He was on an ART regimen, containing zidovudine, lamivudine, and efavirenz combination for 4 years. But patient accidentally started nevirapine and after 10 days he developed maculopapular lesions which were diagnosed as SJS syndrome. There was a history of rash with nevirapine when ART was started initially in 2012. This incident of an adverse event could be assigned a term "probable" according to the WHO-UMC scale for causality assessment as the re-challenge was found positive.
Conclusion: Physicians and patients must be aware of this adverse effect on early diagnosis and treatment.